ScinoPharm Taiwan, Ltd.

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.